



## *Anti-rat CXCL7/Thymus Chemokine-1 Antibody*

### ORDERING INFORMATION

**Catalog Number:** AF1116

**Lot Number:** HYV01

**Size:** 100 µg

**Formulation:** 0.2 µm filtered solution in PBS with 5% trehalose

**Storage:** -20° C

**Reconstitution:** sterile PBS

**Specificity:** rat CXCL7

**Immunogen:** *E. coli*-derived rrCXCL7

**Ig Type:** goat IgG

**Applications:** Neutralization of bioactivity  
Western blot  
Direct ELISA  
Immunohistochemistry

### **Preparation**

Produced in goats immunized with purified, *E. coli*-derived, recombinant rat CXCL7 (rrCXCL7; aa 56 - 107). Rat CXCL7 specific IgG was purified by Rat CXCL7 affinity chromatography.

### **Formulation**

Lyophilized from a 0.2 µm filtered solution in phosphate-buffered saline (PBS) with 5% trehalose.

### **Endotoxin Level**

< 0.1 EU per 1 µg of the antibody as determined by the LAL method.

### **Reconstitution**

Reconstitute with sterile PBS. If 1 mL of PBS is used, the antibody concentration will be 0.1 mg/mL.

### **Storage**

Lyophilized samples are stable for twelve months from date of receipt when stored at -20° C to -70° C. Upon reconstitution, the antibody can be stored at 2° - 8° C for 1 month without detectable loss of activity. Reconstituted antibody can also be aliquotted and stored frozen at -20° C to -70° C in a manual defrost freezer for six months without detectable loss of activity. **Avoid repeated freeze-thaw cycles.**

### **Specificity**

This antibody has been selected for its ability to neutralize rat CXCL7 bioactivity.

### **Neutralization of Rat CXCL7 Bioactivity**

The exact concentration of antibody required to neutralize rrCXCL7 activity is dependent on the cytokine concentration, cell type, growth conditions and the type of activity studied. To provide a guideline, R&D Systems has determined the neutralization dose for this antibody under a specific set of conditions. The **Neutralization Dose<sub>50</sub> (ND<sub>50</sub>)** for this antibody is defined as that concentration of antibody required to yield one-half maximal inhibition of the cytokine activity on a responsive cell line, when that cytokine is present at a concentration just high enough to elicit a maximum response.

The ND<sub>50</sub> for this lot of anti-rat CXCL7 antibody was determined to be approximately 0.8 - 4 µg/mL in the presence of 0.04 µg/mL of rrCXCL7, using BaF/3 cells transfected with recombinant human CXCR-2 gene. The specific conditions are described in the figure legends.

### **Additional Applications**

**Direct ELISA** - This antibody can be used at 0.5 - 1.0 µg/mL with the appropriate secondary reagents to detect rat CXCL7. The detection limit for rrCXCL7 is approximately 0.15 ng/well. In this format, this antibody shows approximately 10% cross-reactivity with rmCXCL7 and less than 1% cross-reactivity with other chemokines tested.<sup>1</sup>



**Western blot** - This antibody can be used at 0.1 - 0.2 µg/mL with the appropriate secondary reagents to detect rat CXCL7. The detection limit for rrCXCL7 is approximately 2 ng/lane under non-reducing and reducing conditions.

**Immunohistochemistry** - This antibody will detect CXCL7 in cells and tissues. The working dilution is 5 - 15 µg/mL. For chromogenic detection of labeling, use R&D Systems' Cell and Tissue Staining Kits (CTS Series).

**Optimal dilutions should be determined by each laboratory for each application.**

FOR RESEARCH USE ONLY. NOT FOR USE IN HUMANS.

**R&D Systems, Inc.**  
**1-800-343-7475**

**Figure 1****Figure 2****Figure 1**

Recombinant rat CXCL7 chemoattracts BaF/3 cells transfected with rhCXCR-2. The ED<sub>50</sub> for this effect is typically 1 - 5 ng/mL.

**Figure 2**

To measure the ability of the antibody to neutralize the chemoattractant activity of rrCXCL7 for hCXCR-2 transfected BaF/3 cells, rrCXCL7 was incubated with various concentrations of the antibody for 15 minutes at room temperature in a 96 well microplate. Following this preincubation period, 75 μL of the cytokine-antibody solution (containing rrCXCL7 at a final concentration of 0.04 μg/mL and antibody at the concentrations indicated) was transferred to the lower compartment of a 96 well chemotaxis chamber (NeuroProbe, Cabin John, MD). The chemotaxis chamber was then assembled using a PVP-free polycarbonate filter (5 micron pore size) and 0.2 x 10<sup>6</sup> cells/well was added to the top chamber. After incubation for 3 hours at 37° C in a 5% CO<sub>2</sub> humidified incubator, the chamber was carefully disassembled. The cells that migrate through to the lower chamber were transferred to a 96 well plate. Chemotaxis was measured by Resazurin (R&D Systems, Catalog # AR002) staining of cells that have migrated through the filter. As shown in figure 2, the ND<sub>50</sub> for this lot of antibody is approximately 0.8 - 4 μg/mL.

<sup>1</sup>rh6Ckine, rm6Ckine, rhBLC/BCA-1, rmBLC, rhBRAK, rmBRAK, rmC10, rhCCL28, rmCCL28, rrCINC-2α, rrCINC-2β, rrCINC-3, rhCKβ8-1, rvCMV UL146, rmCRG-2, rhCTACK, rmCTACK, rhCXCL16, rmCXCL16, rhENA-78, rhEotaxin, rmEotaxin, rhEotaxin-2, rmEotaxin-2, rhEotaxin-3, rhFractalkine, rmFractalkine, rrFractalkine, rhGCP-2, rmGCP-2, rhGROα, rhGROβ, rhGROγ, rhHCC-1, rhHCC-4, rhIL-309, rhIL-8, rplL-8, rcrIP-10, rhIP-10, rhI-TAC, rml-TAC, rmJE, rmKC, rhLeukotactin-1, rrLIX, rmLungkine, rhLymphotactin, rmLymphotactin, rmMARC, rhMCP-1, rhMCP-2, rmMCP-2, rhMCP-3, rhMCP-4, rmMCP-5, rvMCV type 2, rhMDC, rmMDC, rhMIG, rmMIG, rcrMIP-1α, rhMIP-1α, rmMIP-1α, rcrMIP-1β, rhMIP-1β, rmMIP-1β, rhMIP-1δ, rmMIP-1γ, rmMIP-2, rhMIP-3α, rmMIP-3α, rrMIP-3α, rhMIP-3β, rmMIP-3β, rvMIP-I, rvMIP-II, rvMIP-III, rhMPIF-1, rhNAP-2, rhPARC, rhPF4, rcrRANTES, rhRANTES, rmRANTES, rhSDF-1α, rmSDF-1α, rhSDF-1β, rhTARC, rmTARC, rmTCA-3, rhTeck, rmTeck